What did tesamorelin studies find?
Two Phase 3 trials, the large tests near approval, led the way. A 2026 review then brought five trials together.
What is the short answer on tesamorelin?
Researchers made tesamorelin to keep a natural message working longer. They then tested it in adults with HIV. Those adults had added fat around the organs.
Two large trials gave the clearest answer. A daily 2 mg shot cut that fat about 15% [1][2]. The drop held for up to a year. Growth hormone and IGF-1, a liver growth signal, rose [4].
Five trials were brought together in a 2026 review [13]. The studies don’t give the same answer for other people. Claims about other groups don’t have equal proof.
How does the growth signal reach belly fat?
Tesamorelin first reaches a small gland under the brain. It fits one matching place on that gland [4]. The gland then sends out growth hormone.
The liver answers with IGF-1, another growth signal [6]. Together, both signals help the body use deep belly fat. The first step starts under the brain.
A small study checked these steps in 13 men. Each man received 2 mg daily for two weeks. Night growth hormone rose [4].
IGF-1 rose by 181 millionths of a gram in each liter of blood. The IGF-1 rise was a blood-test reading, not a dose. Blood sugar use didn’t clearly change.
Tesamorelin doesn’t put growth hormone into the body. It asks the gland to make its own [6]. That fact helps you compare the two drugs.
What happened in the two large Phase 3 HIV trials?
The first main trial lasted twenty-six weeks. It was Phase 3, a large test near approval. The trial included 412 adults with HIV and added belly fat.
Each person received a daily 2 mg shot. Their deep belly fat fell 15.2%. It rose 5.0% with placebo, a shot containing no tesamorelin. The difference favored tesamorelin.
Triglycerides, one kind of blood fat, fell by 50 milligrams per deciliter. They rose by 9 milligrams per deciliter with placebo. A deciliter means a tenth of a liter.
IGF-1, a liver-made growth signal, rose 81.0% [1]. A longer study ran 52 weeks. It compared 273 people on 2 mg daily with 137 on placebo. Deep belly fat stayed down by 18%.
That fat returned after the drug stopped. Average blood sugar didn’t change enough to matter [2]. A joined Phase 3 check covered 806 people taking HIV drugs. The loss held through 52 weeks [7].
Fat under the skin stayed much the same. People felt less upset about their body shape. The joined check backed the main trials.
Did liver fat change along with belly fat?
One trial followed 50 adults with HIV for six months. They were taking HIV drugs. With 2 mg daily, the scan area of deep belly fat shrank 42 square centimeters. The scan measured area, not weight.
Liver fat also fell by 2.9% [3]. Both kinds of fat fell together. IGF-1 rose as part of the same growth system.
A later check used CT scans, which are detailed x-rays. It ran for 26 weeks. The fat left behind looked healthier on the scans [10]. That finding hasn’t proved less illness.
Blood work gave two more details. One clotting-related reading fell. A hormone from fat cells rose a little [9]. Both moved with the loss of deep belly fat.
Who lost more fat in the 2026 review?
Researchers first joined two Phase 3 trials. They compared 543 people on tesamorelin with 263 on placebo. Here, placebo meant a shot with no tesamorelin.
For deep belly fat, the team chose a cutoff of 140 square centimeters. It wasn’t a care goal. More people on tesamorelin finished below that mark. Researchers were 95% sure tesamorelin improved that chance [11].
By 3 months, researchers still couldn’t predict who would lose more. Neck fat didn’t change the waist result [12]. An early blood test offered no clear answer.
A 2026 review then joined five trials. It reported drops in deep belly fat, trunk fat, and liver fat. Tissue without fat rose as well [13]. The review couldn’t say how much of that was muscle.
No serious harm appeared in those trials. Researchers were 95% sure that deep belly fat fell. Still, five trials can’t settle every long-term risk.
One 2026 review asked about bone and joint care. It found no proof that tesamorelin helps either one [14]. A sports review warned about untested online powders and unknown long-term risks [15].
Sports rules also bar tesamorelin. Neither review added an approved use. See reported safety signals and references and citations.
What haven’t the tesamorelin studies shown?
The strong results came from adults with HIV. They were also taking HIV drugs [1][2][7]. No large finished trial proves the same fat loss for everyone.
A small study in healthy men measured hormones, not fat [4]. It found a rise in IGF-1. So the leap beyond HIV isn’t yet proved [14].
Long use leaves another gap. Trials found no added cancer sign through 52 weeks [2][4]. Still, people with active cancer are told not to use it.
Deep belly fat also returned after treatment stopped [2]. The best evidence covers 26 to 52 weeks. It covers a 2 mg daily shot. It doesn’t cover every person or every use.